ARENTFOX SCHIFF LLP for EQRX INTERNATIONAL, INC.
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Issues and policies impacting innovation in drug development S. 908 (Medicare Drug Price Negotiation Act), all provisions S. 909 (Prescription Drug Price Relief Act of 2021), all provisions S. 1427 (Increasing Access to Biosimilars Act of 2021), regarding Centers for Medicare and Medicaid Services Innovation Center shared savings demonstration projects H.R. 3 (Elijah E. Cummings Lower Drug Costs Now Act), all provisions S. 1898 (Affordable Medications Act), all provisions H.R. 5376 (Build Back Better Act), Title XIII, Subtitle J, regarding drug pricing H.R. 6000 (Cures 2.0 Act), all provisions S. 3799 (PREVENT Pandemics Act), Title V, regarding drug manufacturing
| Lobbyist | Covered position, as disclosed |
|---|---|
| BYRON DORGAN | — |
| JERI FREIRICH New | Legislative Aide, Sen. Roy Blunt (2019); Legislative Correspondent, Sen. Roy Blunt (2018-2019); Staff Assistant, Sen. Roy Blunt (2017-2018) |
| DAN RENBERG | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.